Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 978 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is S  [Clear All Filters]
2021
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..  2021.  Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Wang H, Xu M, Engelhart CA, Zhang X, Yan B, Pan M, Xu Y, Fan S, Liu R, Xu L et al..  2021.  Rediscovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in Mycobacterium tuberculosis.. J Biol Chem. 296:100257.
Chen X, Lee SKoo, Song M, Zhang T, Han MShin, Chen Y-T, Chen Z, Ma X, Tung C-H, Du Y-CNancy.  2021.  RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment.. Mol Ther Oncolytics. 23:277-287.
Jurgens EMatthew, Ketas TJoseph, Zhao Z, Satlin MJoseph, Small CButkus, Sukhu A, Francomano E, Klasse PJohan, Garcia A, Nguyenduy E et al..  2021.  Serologic response to mRNA COVID-19 vaccination in lymphoma patients.. Am J Hematol. 96(11):E410-E413.
Jurgens EMatthew, Ketas TJoseph, Zhao Z, Satlin MJoseph, Small CButkus, Sukhu A, Francomano E, Klasse PJohan, Garcia A, Nguyenduy E et al..  2021.  Serologic response to mRNA COVID-19 vaccination in lymphoma patients.. Am J Hematol. 96(11):E410-E413.
Jurgens EMatthew, Ketas TJoseph, Zhao Z, Satlin MJoseph, Small CButkus, Sukhu A, Francomano E, Klasse PJohan, Garcia A, Nguyenduy E et al..  2021.  Serologic response to mRNA COVID-19 vaccination in lymphoma patients.. Am J Hematol. 96(11):E410-E413.
Athapattu US, Amarasekara CA, Immel JR, Bloom S, Barany F, Nagel AC, Soper SA.  2021.  Solid-phase XRN1 reactions for RNA cleavage: application in single-molecule sequencing.. Nucleic Acids Res. 49(7):e41.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Benjamin B, Sanchez AM, Garg A, Schwer B, Shuman S.  2021.  Structure-function analysis of fission yeast cleavage and polyadenylation factor (CPF) subunit Ppn1 and its interactions with Dis2 and Swd22.. PLoS Genet. 17(3):e1009452.
Benjamin B, Sanchez AM, Garg A, Schwer B, Shuman S.  2021.  Structure-function analysis of fission yeast cleavage and polyadenylation factor (CPF) subunit Ppn1 and its interactions with Dis2 and Swd22.. PLoS Genet. 17(3):e1009452.
Benjamin B, Sanchez AM, Garg A, Schwer B, Shuman S.  2021.  Structure-function analysis of fission yeast cleavage and polyadenylation factor (CPF) subunit Ppn1 and its interactions with Dis2 and Swd22.. PLoS Genet. 17(3):e1009452.
Calderón F, Fairlamb AH, Strange M, Williams P, Nathan CF.  2021.  Surmounting structural barriers to tackle endemic infectious diseases.. J Exp Med. 218(9)